Dogwood Therapeutics, Inc (NASDAQ:DWTX – Get Free Report) shares rose 5.4% during trading on Thursday . The stock traded as high as $1.6050 and last traded at $1.57. Approximately 266,441 shares changed hands during mid-day trading, an increase of 432% from the average daily volume of 50,078 shares. The stock had previously closed at $1.49.
Analysts Set New Price Targets
DWTX has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Dogwood Therapeutics in a report on Tuesday, May 19th. Weiss Ratings downgraded Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $12.00.
Read Our Latest Analysis on DWTX
Dogwood Therapeutics Price Performance
Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) last posted its earnings results on Thursday, May 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. Research analysts predict that Dogwood Therapeutics, Inc will post -0.55 EPS for the current fiscal year.
Institutional Trading of Dogwood Therapeutics
A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP bought a new position in Dogwood Therapeutics, Inc (NASDAQ:DWTX – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. Institutional investors own 9.05% of the company’s stock.
About Dogwood Therapeutics
Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.
Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.
Featured Stories
- Five stocks we like better than Dogwood Therapeutics
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for Dogwood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dogwood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
